Clinical Trial Update: A 6-Week Multicenter Trial Of Varenicline Tartrate For Cognitive Impairment In Subjects With Schizophrenia [Phase 2]

View source ↗

Summary

Pfizer's 6-week Phase 2 multicenter trial of varenicline tartrate for cognitive impairment in schizophrenia has been withdrawn.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Schizophrenia

Drugs mentioned

• Varenicline tartrate (varenicline tartrate)

Snippet

Sponsor: Pfizer | Conditions: Schizophrenia | Phase 2 | Status: WITHDRAWN